NCT01032603 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Donahue SP, Chandler DL, Wu R, Marsh JD, Law C, Areaux RG Jr, Ghasia FF, Li Z, Kraker RT, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group
Eight-Year Outcomes of Bilateral Lateral Rectus Recessions versus Unilateral Recession-Resection in C
Holmes JM, Hercinovic A, Melia BM, Leske DA, Hatt SR, Chandler DL, Dean TW, Kraker RT, Enyedi LB, Wallace DK, Donahue SP, Cotter SA; Pediatric Eye Disease Investigator Group
Improvement in health-related quality of life following strabismus surgery for c
Pediatric Eye Disease Investigator Group; Writing Committee; Donahue SP, Chandler DL, Holmes JM, Arthur BW, Paysse EA, Wallace DK, Petersen DB, Melia BM, Kraker RT, Miller AM
A Randomized Trial Comparing Bilateral Lateral Rectus Recession versus Unilater
Repka MX, Chandler DL, Holmes JM, Donahue SP, Hoover DL, Mohney BG, Phillips PH, Stout AU, Ticho BH, Wallace DK; Pediatric Eye Disease Investigator Group
The Relationship of Age and Other Baseline Factors to Outcome of Initial Surgery for Intermittent Exotropia. Am J Ophthalmol. 2020 Apr;212:153-161. doi: 10.1016/j.ajo.2019.12.008. Epub 2019 Dec 17.

A Randomized Trial of Bilateral Lateral Rectus Recession Versus Unilateral Lateral Rectus Recession With Medial Rectus Resection for Intermittent Exotropia

Details for clinical trial NCT01032603

Clinical trial NCT01032603 - References